Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25023302 | 0.91 | GRIA1 (0.47) | FAAHGRIA1HDAC1HDAC6HDAC3 | |
| SCHEMBL28969085 | 0.91 | GRIA1 (0.47) | FAAHGRIA1HDAC1HDAC6HDAC3 | |
| SCHEMBL25022775 | 0.85 | LPAR3 (0.46) | FAAHGRIA1LPAR3PTPN1LPAR1 | |
| SCHEMBL25023523 | 0.84 | MGLL (0.45) | FAAHHDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL30306745 | 0.84 | SIRT2 (0.49) | FAAH | |
| SCHEMBL24073112 | 0.81 | GRIA1 (0.46) | GRIA1HDAC1HDAC6LPAR3PTPN1 | |
| SCHEMBL25022238 | 0.78 | GRIA1 (0.48) | GRIA1LPAR3LPAR1MGLL | |
| SCHEMBL28969059 | 0.77 | SIRT2 (0.51) | — | |
| SCHEMBL28969062 | 0.77 | SIRT2 (0.51) | — | |
| SCHEMBL30306849 | 0.76 | GRIA1 (0.47) | FAAHGRIA1LPAR3PTPN1LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156780-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11951094-B2 | TLR2 modulator compounds, pharmaceutical compositions and uses thereof | AXIAL THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4171547-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Axial Therapeutics, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TLR2, TLR3, TLR4 | FAAH 2978/4885GRIA1 596/4885HDAC1 599/4885 |
| US-20240156780-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TLR2, TLR3, TLR4 | FAAH 2978/4885GRIA1 596/4885HDAC1 599/4885 |
| US-11951094-B2 | TLR2 modulator compounds, pharmaceutical compositions and uses thereof | TLR2, TLR3, TLR4 | FAAH 2978/4885GRIA1 596/4885HDAC1 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.